Thought leaders discuss patient scenarios and different factors to consider when deciding how to select and utilize bridging therapy in the management of patients with LBCL.
CGTLive®’s Weekly Rewind – September 6, 2024
Review top news and interview highlights from the week ending September 6, 2024.
Cartesian Therapeutics Doses First Patient With mRNA CAR-T Descartes-15 in Trial for R/R Multiple Myeloma
Pending the results of the trial, Cartesian plans to eventually evaluate Descartes-15 for the treatment of autoimmune diseases.
Around the Helix: Cell and Gene Therapy Company Updates – September 4, 2024
Catch up on the latest news, breakthroughs, and announcements from biotechnology companies making advancements in cell and gene therapies.
FDA Activity Recap: August 2024 Features TCR T-Cell Therapy Approval, REMS Modification, the Lifting of a Clinical Hold, and More
Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.
CGTLive®’s Weekly Rewind – August 30, 2024
Review top news and interview highlights from the week ending August 30, 2024.
Orgenesis’ CAR-T ORG-101 Demonstrates Efficacy and Safety in Acute Lymphoblastic Leukemia in Real-World Study in China
Among the treated patients, the complete response (CR) rate in adults was 82% and the CR rate in children was 93%.